Lineage Cell Therapeutics (LCTX) Return on Invested Capital (2014 - 2023)

Lineage Cell Therapeutics' Return on Invested Capital history runs 5 years deep, the most recent figure standing at 0.41% for Q4 2023.

• On a quarterly basis, Return on Invested Capital rose 4.0% year-over-year to 0.41% in Q4 2023; TTM through Dec 2023 was 0.41%, a 4.0% increase from a year earlier, with the FY2022 full-year figure at 3.08%, changed N/A from the prior year.
• Return on Invested Capital grew to 0.41% in Q4 2023 per LCTX's latest filing, from 0.41% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.18% in Q3 2021 and bottomed at 2.52% in Q3 2019.
• The 4-year median for Return on Invested Capital is 0.5% (2023), against an average of 0.85%.
• Across the five-year window, Return on Invested Capital plunged 161 bps in 2022 and jumped 138 bps in 2023, its largest moves.
• Year by year, Return on Invested Capital stood at 0.79% in 2019, then surged by 77 bps to 0.18% in 2021, then plunged by 147 bps to 0.45% in 2022, then gained by 8 bps to 0.41% in 2023.
• Per Business Quant, the three latest LCTX Return on Invested Capital figures stand at 0.41% (Q4 2023), 0.41% (Q3 2023), and 0.5% (Q2 2023).